S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:ACRS

Aclaris Therapeutics News Headlines

$10.10
-0.27 (-2.60%)
(As of 01/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$9.95
$10.55
50-Day Range
$9.74
$15.44
52-Week Range
$9.26
$30.38
Volume
511,213 shs
Average Volume
525,440 shs
Market Capitalization
$618.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.47
Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Aclaris Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACRS
News Sentiment

0.11

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACRS Articles
This Week

2

0

ACRS Articles
Average Week



Aclaris Therapeutics (NASDAQ:ACRS) News Headlines Today

SourceHeadline
MarketBeat logo Analysts Anticipate Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to Announce -$0.36 Earnings Per Share
americanbankingnews.com - January 27 at 9:34 AM
MarketBeat logoAclaris Therapeutics (NASDAQ:ACRS) Sets New 12-Month Low at $9.32
americanbankingnews.com - January 24 at 11:12 AM
MarketBeat logoAclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down to $10.14
americanbankingnews.com - January 19 at 12:01 PM
MarketBeat logoAclaris Therapeutics (NASDAQ:ACRS) Hits New 1-Year Low at $10.08
americanbankingnews.com - January 18 at 5:12 PM
seekingalpha.com logoBed Bath & Beyond, Orphazyme lead postmarket gainers; Gogo, Biogen among losers
seekingalpha.com - January 13 at 6:33 PM
msn.com logoThe Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
msn.com - January 12 at 12:21 PM
MarketBeat logoAclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down to $12.86
americanbankingnews.com - January 12 at 11:54 AM
seekingalpha.com logoAclaris falls on the exit of medical chief
seekingalpha.com - January 11 at 7:07 PM
finance.yahoo.com logoAclaris Therapeutics Provides R&D Update
finance.yahoo.com - January 11 at 7:07 PM
MarketBeat logoAclaris Therapeutics (NASDAQ:ACRS) Sees Unusually-High Trading Volume
americanbankingnews.com - January 11 at 1:28 PM
finance.yahoo.com logoAclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
finance.yahoo.com - December 27 at 7:48 AM
finance.yahoo.com logoIs Aclaris Therapeutics, Inc. (ACRS) Going to Burn These Hedge Funds?
finance.yahoo.com - December 8 at 12:31 PM
finance.yahoo.com logoHere's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
finance.yahoo.com - November 23 at 8:55 AM
finance.yahoo.com logoAclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
finance.yahoo.com - August 27 at 8:24 PM
benzinga.com logoLooking into Aclaris Therapeutics's Return on Capital Employed
benzinga.com - August 27 at 8:24 PM
nasdaq.com logoShould You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?
nasdaq.com - August 5 at 12:59 PM
msn.com logoBRIEF-Aclaris Therapeutics Reports Second Quarter 2021 Financial Results
msn.com - August 5 at 7:58 AM
finance.yahoo.com logoAclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - August 5 at 7:58 AM
finance.yahoo.com logoAclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
finance.yahoo.com - July 30 at 7:36 PM
finance.yahoo.com logoAclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
finance.yahoo.com - July 8 at 9:33 AM
bizjournals.com logoAclaris Therapeutics prices $125M public stock offering
bizjournals.com - June 10 at 2:23 PM
marketwatch.com logoAclaris Therapeutics Down 5% After Plans for Stock Offering
marketwatch.com - June 9 at 6:36 PM
finance.yahoo.com logoAclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
finance.yahoo.com - June 9 at 1:35 PM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Rises Over 1%; Aclaris Therapeutics Shares Plunge
benzinga.com - June 8 at 7:09 PM
finance.yahoo.com logoAclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
finance.yahoo.com - June 8 at 2:08 PM
msn.com logoBRIEF-Aclaris Therapeutics Announces Positive Preliminary Topline Data From Phase 2A Trial Of ATI-1777 For Moderate To Severe Atopic Dermatitis
msn.com - June 8 at 9:07 AM
finance.yahoo.com logoAclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
finance.yahoo.com - June 8 at 9:07 AM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Share Registry?
finance.yahoo.com - May 18 at 7:23 AM
finance.yahoo.com logoAclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 17 at 9:52 AM
finance.yahoo.com logoAclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 7 at 12:44 PM
finance.yahoo.com logoAclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 7 at 7:44 AM
uk.finance.yahoo.com logoAclaris Therapeutics Inc (ACRS) President and CEO Neal Walker Sold $805,200 of Shares
uk.finance.yahoo.com - April 27 at 6:57 AM
finance.yahoo.com logoIs ACRS Stock A Buy or Sell?
finance.yahoo.com - April 26 at 7:23 AM
finance.yahoo.com logoAclaris Therapeutics Stock Appears To Be Significantly Overvalued
finance.yahoo.com - April 1 at 8:23 AM
finance.yahoo.com logoAclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
finance.yahoo.com - March 15 at 8:29 AM
finance.yahoo.com logoAclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - February 25 at 8:29 AM
finance.yahoo.com logoAclaris Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 22 at 9:00 AM
finance.yahoo.com logoAclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 9:06 AM
finance.yahoo.com logoGaining Ground After A Tough Couple Of Weeks
finance.yahoo.com - January 25 at 7:34 PM
bizjournals.com logoAclaris aims to raise $96 million through stock offering after shares soar
bizjournals.com - January 20 at 9:29 PM
bizjournals.com logoAclaris Therapeutics' stock jumps on positive data for drug developed by St. Louis-based unit
bizjournals.com - January 20 at 4:22 PM
finance.yahoo.com logoHow High Is the Blue Sky for Aclaris Stock? Analyst Weighs In
finance.yahoo.com - January 20 at 4:21 PM
finance.yahoo.com logoAclaris Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 20 at 11:21 AM
finance.yahoo.com logoAclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
finance.yahoo.com - January 20 at 11:21 AM
finance.yahoo.com logoAclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis Trial
finance.yahoo.com - January 20 at 6:20 AM
markets.businessinsider.com logoACRS Soars On RA Trial Data, BHVN Disappoints In Alzheimer's Trial, GRTS Joins COVID-19 Vaccine Race
markets.businessinsider.com - January 20 at 1:20 AM
msn.com logoIs Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
msn.com - January 19 at 8:20 PM
bizjournals.com logoAclaris Therapeutics' stock skyrockets 220% on positive data for potential arthritis treatment
bizjournals.com - January 19 at 8:20 PM
finance.yahoo.com logoAclaris Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 19 at 8:20 PM
finance.yahoo.com logoAclaris Triples After Progress in Rheumatoid Arthritis Drug Trial
finance.yahoo.com - January 19 at 8:20 PM
Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.